• 1

Research Projects

RHEACELL develops stem cell-based pharmaceuticals for various indications based on the know-how of TICEBA GmbH, making use of exclusive licenses to patents hold by Harvard University, Cambridge/USA.


Current Research Projects

Mesenchymal Stem Cells

Limbal Stem Cells

Tumor Stem Cells

Product Indication Discovery Preclinical Phase I/II Phase III Marketed
CVU auto: APZ2 Chronic Venous Ulcers - Autologous
 
 
 
 
CVU allo: allo-APZ2-CVU Chronic Venous Ulcers - Allogeneic
 
 
 
 
DFU: allo-APZ2-DFU Diabetic Foot Ulcers - Allogeneic
 
 
 
 
PAOD: allo-APZ2-PAOD Peripheral Arterial Occlusive Disease - Allogeneic
 
 
 
 
ACLF: allo-APZ2-ACLF Acute-on-Chronic Liver Failure - Allogeneic
 
 
 
 
RDEB: allo-APZ2-EB 1 2 4 Epidermolysis Bullosa - Allogeneic
 
 
 
 
LSCD: LSC2 1 2 3 4 Limbal Stem Cell Deficiency - Allogeneic
 
 
 
 
- Oncology (Therapeutic Monoclonal Antibodies)
 
 
 
 
1 EMA Orphan Drug Designation
2 FDA Orphan Drug Designation
3 FDA Fast Track Designation
4 FDA Clinical Trial Approval
Today
Future
 
 
 
 
 
Product Indication Discovery Preclinical Phase I/II Phase III Marketed
CVU auto: APZ2 CVU - Autologous
 
 
 
 
CVU allo: allo-APZ2-CVU CVU - Allogeneic
 
 
 
 
DFU: allo-APZ2-DFU DFU - Allogeneic
 
 
 
 
PAOD: allo-APZ2-PAOD PAOD - Allogeneic
 
 
 
 
ACLF: allo-APZ2-ACLF ACLF - Allogeneic
 
 
 
 
RDEB: allo-APZ2-EB 1 2 4 EB - Allogeneic
 
 
 
 
LSCD: LSC2 1 2 3 4 LSCD - Allogeneic
 
 
 
 
- mAB
 
 
 
 
1 EMA Orphan Drug Designation
2 FDA Orphan Drug Designation
3 FDA Fast Track Designation
4 FDA Clinical Trial Approval
Today
Future
 
 
 
 
 

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.